KDR and neoplasm: Anlotinib, a small molecule multi-target tyrosine kinase inhibitor (TKI), demonstrates potent inhibition against vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), fibroblast growth factor receptor (FGFR), and c-Kit, resulting in antitumor angiogenic effects and suppression of tumor growth [6].